header-20.jpg
Grants

Upfront PSMA Alliance

Upfront PSMA Alliance: Using theranostics early to eradicate prostate cancer and developing novel strategies for PSMA-negative disease

The first aim of the study will be to conduct an Australian wide randomised phase II study in patients with newly diagnosed metastatic prostate cancer. The study will compare whether the addition of LuPSMA to the current standard-of-care of androgen deprivation therapy and chemotherapy will improve patient outcomes.

In a second aim, patients with high-risk localised prostate cancer will be given LuPSMA prior to undergoing a radical prostatectomy. Scanning and pathology findings will be evaluated to see whether this is a successful strategy to reduce recurrence rates.

Investigators

A/Prof Arun Azad
(Co PI)

Peter MacCallum Cancer Centre and University of Melbourne
Prof Michael Hofman
(Co PI)
Peter MacCallum Cancer Centre and University of Melbourne
Dr Ian Vela
(Team member)
APCRC-Q, IHBI, QUT, TRI

Administering Institution

Peter MacCallum Cancer Centre

Duration

2019 - 2021

Funding

Cancer Australia and Movember Foundation $5 400 000